-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UKfGvIl6LB/kwJ6jTMlhGjWlYFWV/1nxMHA66eQpkFAKhEYyk+I7v90dMUzWTZFC 50fPh5MBdhUJcBKeKGwd+A== 0001144204-05-018043.txt : 20050603 0001144204-05-018043.hdr.sgml : 20050603 20050603154143 ACCESSION NUMBER: 0001144204-05-018043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050531 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20050603 DATE AS OF CHANGE: 20050603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMCOR PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000761237 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621742885 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23553 FILM NUMBER: 05877612 BUSINESS ADDRESS: STREET 1: 6175 LUSK BOULEVARD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858 410-5601 MAIL ADDRESS: STREET 1: 6175 LUSK BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: PHOTOGEN TECHNOLOGIES INC DATE OF NAME CHANGE: 19970529 8-K 1 v019589_8k.htm Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities Act of 1934
 
 Date of Report (Date of earliest event reported) - May 31, 2005

IMCOR PHARMACEUTICAL CO.
 (Exact name as specified in its charter)

 
NEVADA
0-23553
62-1742885
(State or other jurisdiction of
Incorporation or organization)
(Commission
File Number)
(IRS Employer
Identification No.)
 
 
6175 Lusk Boulevard
San Diego, CA
92101
(Address of principal executive offices)
(Zip Code)

(858) 410-5601
 (Registrants' telephone number, including area code)



 (Former name or former address, if changed since last report)




Item 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

The employment of Taffy J. Williams, Ph.D., the Chief Executive Officer, President and acting principal financial officer of IMCOR Pharmaceutical Co. (the “Company”) ended as of May 31, 2005.

Item 8.01 OTHER EVENTS.

As reported in the Company’s Form 10-QSB for the quarter ended March 31, 2005, the Company adopted a restructuring plan in April and May which involved disposing of its excess furniture, fixtures and equipment, vacating its premises in San Diego, California, curtailing the Company’s operations, suspending manufacturing operations and the laying-off of a majority of the Company’s full and part time employees or consultants. The Company has continued to proceed under this plan and has notified the Federal Drug Administration of the ceasing of its commercial activities and temporarily suspending its manufacturing operations for Imagent® (perflexane lipid microspheres). The Company’s board of directors has authorized the taking of any actions necessary to effectuate the winding down of the Company’s operations.




SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.
 
     
  IMCOR PHARMACEUTICAL CO.
 
 		  
 		  
 
Dated: June 3, 2005 By:   /s/ Larry D. Grant
 
Larry D. Grant
Treasurer and Assistant Secretary

 

 -----END PRIVACY-ENHANCED MESSAGE-----